Cambridge Healthtech Institute第三届

Oligonucleotide Discovery and Delivery

( 低聚核苷酸疗法的创药与运输 )

适体、反义与RNA疗法之开发与运输技术的进步

2018年3月26-28日 | Boston Marriott Cambridge | 马萨诸塞州剑桥

低聚核苷酸疗法长久以来被认为是形成第三大药物发展平台的存在,尤其专注于藉由标的RNA转录产物或基因体自身来调节基因表现方面。使用核酸作为治疗手段的关键特徵在于进入小分子药物及生物制剂无法对应的「无法药物化」领域,让药物开发人员得以开发目前有所受限或缺乏治疗选项的疾病领域。可惜由于第一代及第二代分子的效力与安全性方面浮现问题,目前为止低聚核苷酸疗法仍未对药物开发界造成剧烈影响。然而随著核酸药物与运送技术领域研究的进步,使用化学修饰与结合技术提升稳定性、生体可用性、特异性、效力,开拓了通往新世代低聚核苷酸疗法的道路。有了这些进展,以及稳健发展的环境、数项可能获得核可的晚期临床试验产品,再度提高了对低聚核苷酸疗法开发的关心度。

有了过去的显著成果,CHI很荣幸地将在3月26日~28日举办第三届低聚核苷酸与胜肽疗法年会。与会者可在本会议中与从事低聚核苷酸疗法发现与开发相关工作的研究者共聚一堂,针对核酸合成、药物化学、运输等领域中,技术面及研究面的进步、临床前及临床研究成果等主题进行热烈讨论。

Who should attend: Executives, Directors, Managers, and Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Oligonucleotide Therapeutics, Immunotherapy, Gene Therapy, Gene Editing and Rare Diseases.

Topics will include, but are not limited to:

Therapeutic Oligonucleotides - Coverage Includes:

  • Antisense single-stranded DNA/RNA oligonucleotides (ASOs)
  • siRNA
  • mRNA
  • ncRNA
  • Aptamers

Part 1: Therapeutic Oligonucleotide Discovery and Development

  • Oligonucleotides for:
    • RNA modulation
    • Antivirals
    • Splicing modulation and exon skipping
    • DNAi
    • Gene editing
      • CRISPR/Cas9
  • Oligonucleotide Synthesis and Chemistry
  • Aptamer Therapeutics
  • Preclinical and Clinical Studies
  • Combination Strategies

Part 2: Delivery

  • Chemical Modifications and Conjugation
    • Improving stability, bioavailability, specificity and potency
  • Improved Oligonucleotide Delivery Methods
    • Nanomaterial-based delivery
    • Non-viral delivery systems
    • Small molecule based delivery
    • Delivery methods for non-hepatic targets
      • Blood-brain barrier
    • Delivery of large nucleic acids

Part 3: Oligonucleotides for Cancer Immunotherapy

  • RNA-Based Vaccines
    • Chemical modifications
    • Immuno-stimulatory adjuvants and co-stimulatory molecules
      • Toll-like receptor agonists
      • Targeting the STING pathway
    • Delivery of RNA vaccines
    • Non-viral delivery strategies
  • Dendritic Cell Vaccines
  • Preclinical and Clinical Combination Studies with Checkpoint Inhibitors
  • Novel Agents Inducing Immune Response
  • Novel Targets for Immunotherapy Development

The deadline for submission is September 15, 2017.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

* 活动内容有可能不事先告知作更动及调整。